

# invitation

---



## **Diagnostic and therapeutic innovation in B-cell malignancies**

**How to identify and treat the  
high-risk CLL patient?**

Understanding the biology of high-risk CLL anno 2016 • Overview of current treatment options in high-risk CLL • Case based approach and practical guidance of novel treatment options in high-risk CLL

---

**THURSDAY, NOVEMBER 3<sup>rd</sup> 2016**

Paushuize, Utrecht, The Netherlands  
[www.B-cellsymposium2016.nl](http://www.B-cellsymposium2016.nl)



## Diagnostic and therapeutic innovation in B-cell malignancies

How to identify and treat the high-risk CLL patient?

With recent advances in oncology and especially in Chronic Lymphocytic Leukemia (CLL), we are now on the beginning of a new era. Better understanding of the biology of CLL have led to the rapid development of several diagnostic and therapeutic innovations and are finding its way into daily clinical practice.

To give an overview of the wealth of new data and to better understand these advances in oncology, we would like to invite you to join and participate in a dynamic and informative symposium “Diagnostic & therapeutic innovation in B-cell malignancies”.

Last year, the symposium was focused around novel insights regarding the biology, the role of several signaling pathways and microenvironmental interactions in B-cell malignancies. This year, well known international and local experts will present and discuss the latest developments in both diagnostic as well as therapeutic approaches in high-risk CLL. The symposium will cover a range of topics, from understanding the biology of high-risk CLL, to the practical guidance of treatment options in high-risk CLL, all in order to address the question: “How to identify and treat the high-risk CLL patient?”

The symposium will be led by chairman Prof. Dr. Arnon Kater, professor of Internal Medicine, specializing in translational hematology, and chair of the Dutch CLL working group at the Haemato Oncology Foundation for Adults in the Netherlands (HOVON).

We look forward to welcoming you to what will surely be an informative symposium and a fantastic learning experience.

*“Advances in Oncology”: A series of cross-country collaborative educational symposia to educate (hemato)-oncologists on recent advances in oncology.*

09.00 – 09.45	Welcome & Coffee
09.45 – 10.00	<b>Introduction by chair and pre-questions</b> Prof. Dr. A. Kater (Amsterdam, The Netherlands)
10.00 – 11.30	<b>Understanding high-risk CLL in 2016</b> Including diagnostic innovation in CLL Dr. D. Rossi (Bellinzona, Switzerland) Prof. Dr. R. Rosenquist (Uppsala, Sweden)
11.30 – 12.00	<b>Overview of diagnostic innovation in CLL - The Netherlands</b> Dr. A. Eijkelenboom (Nijmegen, The Netherlands)
12.00 – 12.30	<b>Panel Discussion and post-questions</b> Chair: Prof. Dr. A. Kater, Dr. E.J. de Kruijf (Ede, The Netherlands) Panel: Dr. D. Rossi, Prof. Dr. R. Rosenquist, Dr. A. Eijkelenboom
12.30 – 13.30	Lunch
13.30 – 13.40	<b>Pre-questions</b> Dr. E.J. de Kruijf
13.40 – 14.10	<b>Understanding current treatment options in high risk CLL patients – HOVON guidelines</b> Prof. Dr. A. Kater
14.10 – 14.40	<b>Idelalisib as treatment option in high risk CLL patients</b> Including interactive idelalisib case discussion Prof. Dr. A. Janssens (Leuven, Belgium)
14.40 – 15.10	<b>Ibrutinib as treatment option in high risk CLL patients</b> Including interactive ibrutinib case discussion Dr. R. Mous (Utrecht, The Netherlands)
15.10 – 15.40	Coffee
15.40 – 16.10	<b>AlloSCT as treatment option in high risk CLL patients</b> Including Interactive AlloSCT case discussion Dr. M. van Gelder (Maastricht, The Netherlands)
16.10 – 16.40	<b>Panel discussions and post-questions</b> Chair: Prof. Dr. A. Kater, Dr. E.J. de Kruijf Panel: Prof. Dr. A. Janssens, Dr. R. Mous, Dr. M. van Gelder
16.40 – 16.45	Closure

**Date** Thursday November 3<sup>rd</sup> 2016

**Venue** Paushuize, Kromme Nieuwegracht 49, 3512 HE Utrecht, The Netherlands  
[www.paushuize.nl](http://www.paushuize.nl).

**Registration** Free of charge registration [www.b-cellsymposium2016.nl](http://www.b-cellsymposium2016.nl)  
We kindly request you to register before October 31<sup>st</sup>, 2016.

**Confirmation** Immediately after online registration you will receive a confirmation by e-mail. Mid-October you will receive the joining instructions.

**Accreditation** Will be applied for at the following association and society:  
The Netherlands Association of Internal Medicine (NIV) and the Dutch National Society for Pathology (NVVP).

**Organisation and information** This symposium is an initiative of Gilead:  
Viñoly Tower Floor 9, Claude Debussylaan 22, 1082 MD Amsterdam,  
Telephone + 31 20 718 3650, [www.gilead.com](http://www.gilead.com).

**Information regarding your registration** For information with regard to your registration please contact: Cygnea, Postbus 218, 2870 AE Schoonhoven,  
Telephone +31 182 320 126, E-mail: [b-cell@cygnea.nl](mailto:b-cell@cygnea.nl), [www.cygnea.nl](http://www.cygnea.nl).

**Parking** Parking is possible at garage Springweg.

**Public transport** You can travel to Utrecht Central Station. From here you can take a bus or walk to the venue (both <10 minutes).

You will receive a detailed route description to the venue with your confirmation prior to the meeting.